Product Name: GOAT POX VACCINE, LIVE

Type: Live Vaccine (Attenuated)

COMPOSITION

• Active Ingredient: Attenuated goat pox virus strain (CVCC AV41 Strain)
• Virus Content: Each dose contains ≥ 10^3.5 TCID₅₀
• Presentation: Freeze-dried (lyophilized) sponge-like mass that dissolves rapidly when reconstituted with diluent

DESCRIPTION

GOAT POX VACCINE, LIVE is a live attenuated vaccine containing the goat pox virus strain CVCC AV41, which has been weakened through serial passage in cell culture to reduce virulence while retaining immunogenicity . This vaccine provides reliable protection against goat pox and sheep pox, both highly contagious viral diseases affecting small ruminants worldwide .

Goat Pox Overview: Goat pox, caused by the Goatpox virus (GTPV) from the Poxviridae family, is a highly contagious disease that significantly impacts livestock health and agricultural economies, particularly in developing regions . The disease is characterized by fever, generalized skin lesions (pox lesions), respiratory distress, and high morbidity and mortality rates, especially in young animals. Recent GTPV outbreaks in previously eradicated areas underscore the critical need for effective vaccination programs .

Vaccine Strain Characteristics: The CVCC AV41 strain is a well-characterized attenuated goat pox virus strain used extensively in commercial vaccines. This strain has been modified to be non-pathogenic while maintaining strong immunogenic properties. It induces a robust immune response without causing clinical disease in healthy animals .

Cross-Protection: This vaccine provides protection not only against goat pox in goats but also against sheep pox in sheep, due to the close antigenic relationship between goat pox virus and sheep pox virus .

Onset and Duration of Immunity: Immunity develops rapidly, typically within 4 to 5 days following vaccination . The protective immunity lasts for a minimum of 12 months, making annual revaccination necessary to maintain protection in endemic areas .

Cross-Species Application: The goat pox vaccine (CVCC AV41 strain) has also been developed for the prevention of bovine lumpy skin disease (LSD). When used for this purpose, the virus content per dose must be adjusted to not less than 10^4.5 TCID₅₀ per animal .

INDICATIONS
GOAT POX VACCINE, LIVE is indicated for active immunization of :

• Goats: Prevention of goat pox
• Sheep: Prevention of sheep pox
• Emergency Vaccination: In flocks with active pox outbreaks, healthy animals can be vaccinated to limit disease spread

DOSAGE & ADMINISTRATION

For intradermal or subcutaneous administration. Use aseptic technique. Reconstitute the vaccine with sterile physiological saline (0.9% NaCl) or the provided diluent just before use .

Reconstitution:

• Reconstitute according to the number of doses indicated on the vial label
• Dilute with physiological saline (or injection water) to a final volume of 0.5 ml per dose
• Use the reconstituted vaccine immediately; do not store for later use

Recommended Dosage by Species and Route:

Vaccination Schedule:

• Primary Vaccination: Kids and lambs should be vaccinated at 4 months of age or older
• Booster Vaccination: Annual revaccination is required to maintain immunity
• Breeding Animals: Ideally vaccinate after the kidding/lambing season or before the breeding season
• Emergency Vaccination: During outbreaks, healthy animals can be vaccinated immediately

RECENT RESEARCH FINDINGS

A 2024 study investigating live attenuated goat pox vaccination in pregnant Murcia-Granada goats reported important safety findings :

• Standard Dose Safety: Goats receiving the standard vaccine dose (0.5 ml) experienced no abortions or vaccine-related side effects, with normal body temperatures maintained throughout the observation period
• Double Dose Risks: In goats administered a double dose (0.9 ml), 37% experienced abortions and displayed clinical signs of GTPV infection, including skin lesions (pox lesions) and elevated body temperatures. Molecular analysis confirmed the vaccine strain as the infection source, ruling out external contamination
• Conclusion: Adherence to standard vaccine dosages is critical in pregnant goats to prevent adverse outcomes

WITHDRAWAL PERIODS

• Meat: 0 days
• Milk: 0 hours

PRECAUTIONS & CONTRAINDICATIONS

• Do not use in animals that are sick, febrile, malnourished, or showing clinical signs of disease
• Pregnant Animals: Use with caution. Standard vaccine dosage is generally considered safe, but double dosage should be strictly avoided
• Pregnant Animals (Late Gestation): Avoid vaccination in the last 2 weeks of gestation to minimize stress-related complications
• Side Effects: A small, hard lump may appear at the injection site and typically resolves within 10-14 days
• Vaccine Stability: The reconstituted vaccine should be used within 8 hours to maintain full potency
• Operator Safety: For veterinary use only. Avoid self-injection. Use sterile needles and syringes for each animal to prevent disease transmission.
• Storage: Store at -15°C or below for 24 months stability; or at 2-8°C for 18 months stability . Protect from light. Do not freeze after reconstitution.
• Disposal: Used vaccine vials, needles, and syringes should be disposed of by incineration or other approved methods for biological waste.
• Keep out of reach of children.

Target Species: Goats, Sheep

Pack Sizes: 25, 50, 100 doses per vial

PRODUCT SUMMARY
GOAT POX VACCINE, LIVE Vaccine Live Vaccine Attenuated goat pox virus strain (CVCC AV41 Strain). Virus content in each dose ≥10^3.5TCID₅₀ Livestock

FOR VETERINARY USE ONLY